Background and Objectives: The finding from randomized controlled trials showing that no difference of drug-eluting stent (DES) compared to patients treated with bare metal stents in the development of stent thrombosis (ST) could not be applicable to the real-world setting. The aim of this study was to evaluate the incidence, clinical characteristics, and clinical outcome of ST after implantation of TAXUSTM stents in routine clinical practice. Materials and Methods: This was a retrospective single center cohort study. The 1,584 patients who underwent successful TAXUSTM stent implantation (2,513 lesions treated) between May 2004 and Dec 2006 were investigated. Results: ST was developed in 18 patients (1.14%) from 1,584 patients. Acute ST was in 1 patient (0.06%), subacute ST was in 9 patients (0.57%), and late ST was in 8 patients (0.51%). Sixteen patients who developed ST were under the medication of the dual antiplatelet agents. The incidence of ST in the patients of acute coronary syndrome (ACS) showed the higher tendency than those of stable coronary disease. Mean follow-up duration was 13.3 months. There were 13 myocardial infarction and 3 deaths attributable to ST. Conclusion: The cumulative incidence of ST which confirmed by angiography after successful TAXUSTM stent implantation in consecutive ���real-world��� patients was substantially higher than the rate reported in clinical trials. The patient of ACS should be treated more aggressively, because the risk of stent thrombosis was higher than those of stable angina. The large prospective study for the identification of predictors of DES thrombosis should be conducted.